Vitamin D supplementation in primary hyperparathyroidism: effects on 1,25(OH)
25 hydroxyvitamin D
Calcitriol
Cholecalciferol
Primary hyperparathyroidism
Vitamin D supplementation
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
received:
16
04
2024
accepted:
20
06
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
In patients with Primary Hyperparathyroidism (PHPT) vitamin D deficiency has been associated with more severe presentations. Our aim was to investigate the effects of Vitamin D supplementation on mineral homeostasis and related hormones in individuals with and without PHPT. Individuals with and without PHPT (CTRL) received 14,000 IU/week of oral vitamin D 70 PHPT patients and 75 CTRL were included, and 55 PHPT and 64 CTRL completed the 12-week protocol. After the intervention, there were significant increases in the FGF23 levels (PHPT: 47.9 ± 27.1 to 76.3 ± 33.3; CTRL: 40.5 ± 13.9 to 59.8 ± 19.8 pg/mL, p < 0.001), and significant decreases in 1,25(OH) The weekly administration of 14,000 IU of Vitamin D3 was safe and efficient to increase in 25OHD levels in both groups. However, a paradoxical decrease in 1,25(OH)
Identifiants
pubmed: 38922369
doi: 10.1007/s40618-024-02422-2
pii: 10.1007/s40618-024-02422-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
ID : 2017/19019-4
Informations de copyright
© 2024. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Özbey N et al (2006) Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg 30:321–326
doi: 10.1007/s00268-005-0239-y
pubmed: 16467981
Untch BR et al (2007) Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 142:1022–1026
doi: 10.1016/j.surg.2007.09.026
pubmed: 18063090
Priya G et al (2008) Clinical and laboratory profile of primary hyperparathyroidism in India. Postgrad Med J 84:34–39
doi: 10.1136/pgmj.2007.062653
pubmed: 18230749
Lang BHH, Lo CY (2010) Vitamin D3 deficiency is associated with late-onset hypocalcemia after minimally invasive parathyroidectomy in a vitamin D borderline area. World J Surg 34:1350–1355
doi: 10.1007/s00268-009-0377-8
pubmed: 20054540
Rolighed L et al (2014) Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 99:1072–1080
doi: 10.1210/jc.2013-3978
pubmed: 24423366
Bilezikian JP et al (2022) Management of Primary Hyperparathyroidism. J Bone Miner Res 37:2391–2403
doi: 10.1002/jbmr.4682
pubmed: 36054638
Kabadi UM (2020) Low 25-Hydroxyvitamin D in primary hyperparathyroidism: enhanced conversion into 1,25-hydroxyvitamin D may not be ‘true’ deficiency. JBMR plus 4:e10415
doi: 10.1002/jbm4.10415
pubmed: 33210066
pmcid: 7657390
Song A et al (2021) Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocrinol Invest 44:1667–1677
doi: 10.1007/s40618-020-01473-5
pubmed: 33453021
Holick MF et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930
doi: 10.1210/jc.2011-0385
pubmed: 21646368
Shimada T et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435
doi: 10.1359/JBMR.0301264
pubmed: 15040831
Walton RJ, Bijvoet OLM (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet (London, England) 2:309–310
doi: 10.1016/S0140-6736(75)92736-1
pubmed: 50513
Goltzman D, Mannstadt M, Marcocci C (2018) Physiology of the calcium-parathyroid hormone-vitamin D axis. Front Horm Res 50:1–13
doi: 10.1159/000486060
pubmed: 29597231
Singh RJ, Kumar R (2003) Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc 78:826–829
doi: 10.4065/78.7.826
pubmed: 12839077
Yamashita H et al (2004) Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 151:55–60
doi: 10.1530/eje.0.1510055
pubmed: 15248822
Tebben PJ, Singh RJ, Clarke BL, Kumar R (2004) Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 79:1508–1513
doi: 10.4065/79.12.1508
pubmed: 15595334
Witteveen JE, Van Lierop AH, Papapoulos SE, Hamdy NAT (2012) Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur J Endocrinol 166:55–60
doi: 10.1530/EJE-11-0523
pubmed: 21984611
Kobayashi K et al (2006) Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 154:93–99
doi: 10.1530/eje.1.02053
pubmed: 16381997
Nagata Y et al (2019) Attenuated dentin matrix protein 1 enhances fibroblast growth factor 23 in calvaria in a primary hyperparathyroidism model. Endocrinology 160:1348–1358
doi: 10.1210/en.2019-00017
pubmed: 30916761
Nagata Y et al (2022) Parathyroid hormone regulates circulating levels of sclerostin and FGF23 in a primary hyperparathyroidism model. J Endocr Soc 6:1–10
doi: 10.1210/jendso/bvac027
Alshayeb H et al (2014) Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol. J Clin Endocrinol Metab 99:E1830–E1837
doi: 10.1210/jc.2014-1308
pubmed: 24960544
pmcid: 4184071
Nygaard B et al (2014) Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial. PLoS One 9:e102965
doi: 10.1371/journal.pone.0102965
pubmed: 25166750
pmcid: 4148309
Kamelian T, Saki F, Jeddi M, Dabbaghmanesh MH, Omrani GHR (2018) Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial. J Endocrinol Invest 41:299–306
doi: 10.1007/s40618-017-0739-2
pubmed: 28795342
Charoenngam N, Rujirachun P, Holick MF, Ungprasert P (2019) Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis. Osteoporos Int 30:2183–2193
doi: 10.1007/s00198-019-05102-7
pubmed: 31372708
Zittermann A, Berthold HK, Pilz S (2021) The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr 75:980–987
doi: 10.1038/s41430-020-00725-0
pubmed: 32855522
Ratsma DMA, Muller M, Koedam M, Zillikens MC, van der Eerden BCJ (2023) In vitro regulation of fibroblast growth factor 23 by 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D synthesized by osteocyte-like MC3T3-E1 cells. Eur J Endocrinol 189:448–459
doi: 10.1093/ejendo/lvad131
pubmed: 37796032
De Niet S et al (2018) A randomized study to compare a monthly to a daily administration of vitamin D
doi: 10.3390/nu10060659
pubmed: 29882841
pmcid: 6024703
Zittermann A, Ernst JB, Birschmann I, Dittrich M (2015) Effect of vitamin D or activated vitamin D on circulating 1,25-dihydroxyvitamin D concentrations: a systematic review and metaanalysis of randomized controlled trials. Clin Chem 61:1484–1494
doi: 10.1373/clinchem.2015.244913
pubmed: 26510958
Trummer C et al (2017) Effects of vitamin D supplementation on IGF-1 and calcitriol: a randomized-controlled trial. Nutrients 9:623
doi: 10.3390/nu9060623
pubmed: 28629132
pmcid: 5490602
Okai GG et al (2022) LC-MS/MS reduces interference by high levels of 25(OH)D and its metabolites on measured 1,25(OH)2D. Steroids 187:109095
doi: 10.1016/j.steroids.2022.109095
pubmed: 35908594
Martineau AR et al (2019) Differential effects of oral boluses of vitamin D2 vs vitamin D3 on vitamin D metabolism: a randomized controlled trial. J Clin Endocrinol Metab 104:5831–5839
doi: 10.1210/jc.2019-00207
pubmed: 31199458
pmcid: 6797055
Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF (2013) Serum concentrations of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. J Clin Endocrinol Metab 98:973–979
doi: 10.1210/jc.2012-2114
pubmed: 23386645
pmcid: 3590486
Bislev LS et al (2018) The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial. Endocrine 62:182–194
doi: 10.1007/s12020-018-1659-4
pubmed: 30043092
Stubbs JR, Zhang S, Friedman PA, Nolin TD (2014) Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD. Clin J Am Soc Nephrol 9:1965–1973
doi: 10.2215/CJN.03130314
pubmed: 25183657
pmcid: 4220759
Castellano E et al (2017) Nephrolithiasis in primary hyperparathyroidism: a comparison between silent and symptomatic patients. Endocr Pract 23:157–162
doi: 10.4158/EP161476.OR
pubmed: 27819765
Isidro ML, Ruano B (2009) Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 36:305–310
doi: 10.1007/s12020-009-9211-1
pubmed: 19598008
Corbetta S et al (2005) Risk factors associated to kidney stones in primary hyperparathyroidism. J Endocrinol Invest 28:122–128
doi: 10.1007/BF03345354
pubmed: 15887857
Minisola S, Gianotti L, Bhadada S, Silverberg SJ (2018) Classical complications of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab 32:791–803
doi: 10.1016/j.beem.2018.09.001
pubmed: 30665547
Shah VN, Shah CS, Bhadada SK, Sudhakar Rao D (2014) Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf) 80:797–803
doi: 10.1111/cen.12398
pubmed: 24382124